Revance Therapeutics Inc (RVNC): These Numbers Show Where NASDAQ:RVNC Stock Is Going Next

Revance Therapeutics Inc (NASDAQ: RVNC) is -53.58% lower on its value in year-to-date trading and has touched a low of $5.72 and a high of $37.98 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RVNC stock was last observed hovering at around $8.43 in the last trading session, with the day’s gains setting it 0.14% off its average median price target of $25.00 for the next 12 months. It is also 79.6% off the consensus price target high of $42.00 offered by 12 analysts, but current levels are 4.78% higher than the price target low of $9.00 for the same period.

Currently trading at $8.57, the stock is 14.39% and 10.41% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.12 million and changing 1.66% at the moment leaves the stock -58.65% off its SMA200. RVNC registered -55.34% loss for a year compared to 6-month loss of -66.19%. The firm has a 50-day simple moving average (SMA 50) of $4.39 and a 200-day simple moving average (SMA200) of -$2.79.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a 17.56% gain in the last 1 month and extending the period to 3 months gives it a -31.71%, and is 6.06% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.71% over the week and 7.19% over the month.

Revance Therapeutics Inc (RVNC) has around 534 employees, a market worth around $752.53M and $214.16M in sales. Profit margin for the company is -193.42%. Distance from 52-week low is 49.83% and -77.44% from its 52-week high. The company has generated returns on investments over the last 12 months (-114.06%).

Revance Therapeutics Inc (RVNC) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Revance Therapeutics Inc (RVNC) is a “Buy”. 12 analysts offering their recommendations for the stock have an average rating of 1.42, where 2 rate it as a Hold and 1 think it is a “Overweight”. 9 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Revance Therapeutics Inc is expected to release its quarterly report on 02/27/2024.The EPS is expected to grow by 27.04% this year.

Revance Therapeutics Inc (RVNC) Top Institutional Holders

The shares outstanding are 82.39M, and float is at 78.30M with Short Float at 16.69%.

Revance Therapeutics Inc (RVNC) Insider Activity

A total of 16 insider transactions have happened at Revance Therapeutics Inc (RVNC) in the last six months, with sales accounting for 9 and purchases happening 7 times. The most recent transaction is an insider sale by Moxie Dwight,the company’sSVP, GC & Secretary. SEC filings show that Moxie Dwight sold 11,000 shares of the company’s common stock on Sep 06 at a price of $17.06 per share for a total of $0.19 million. Following the sale, the insider now owns 44066.0 shares.

Revance Therapeutics Inc disclosed in a document filed with the SEC on Sep 05 that Moxie Dwight (SVP, GC & Secretary) sold a total of 23,853 shares of the company’s common stock. The trade occurred on Sep 05 and was made at $17.81 per share for $0.42 million. Following the transaction, the insider now directly holds 55066.0 shares of the RVNC stock.

Still, SEC filings show that on Aug 03, Foley Mark J (CEO) disposed off 26,279 shares at an average price of $22.57 for $0.59 million. The insider now directly holds 840,375 shares of Revance Therapeutics Inc (RVNC).

Revance Therapeutics Inc (RVNC): Who are the competitors?

The company’s main competitors (and peers) include Ionis Pharmaceuticals Inc. (IONS) that is trading 34.15% up over the past 12 months. Biogen Inc. (BIIB) that is -7.59% lower over the same period.